|08/04/16||T2 Biosystems to Present at the Canaccord Genuity Growth Conference|
|LEXINGTON, Mass., Aug. 04, 2016 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) today announced that John McDonough, president and chief executive officer, and Shawn Lynch, chief financial officer, are scheduled to attend and present at the Canaccord Genuity Growth Conference on Thursday, August 11, 2016, at 8:30 a.m. ET in Boston.
A live, listen-only webcast of the presentation may be accessed by visiting the Investors/Events & Presentations section of the Company’s website at ww... |
|08/01/16||T2 Biosystems Reports 2016 Second Quarter, Six-Month Results|
|LEXINGTON, Mass., Aug. 01, 2016 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a company developing innovative diagnostic products to improve patient health, today reported operating highlights and financial results for the second quarter and six months ended June 30, 2016. Recent operational highlights included:
During the second quarter, the Company received commitments for the adoption of the T2Candida® Panel and the T2Dx® Instrument with four new hospitals and hospital syst... |
|07/21/16||T2 Biosystems Announces 2016 Second Quarter and Six-Month Results Release and Conference Call Date|
|LEXINGTON, Mass., July 21, 2016 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) today announced that it will release its 2016 second quarter and six-month financial results after the market closes on Monday, August 1, 2016. In conjunction with the release, the Company will host a conference call with the investment community at 4:30 p.m. Eastern Time on Monday, August 1, 2016, to discuss the financial results and other business developments.
Interested parties may access the live cal... |
|07/18/16||T2 Biosystems Announces Research and Development Collaboration with Bayer to Advance Drug Monitoring and Biomarker Discovery for Blood Coagulation Disorders|
|LEXINGTON, Mass., July 18, 2016 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a company developing innovative diagnostic products to improve patient health, has signed a multi-year agreement to provide T2 Biosystems’ T2 Magnetic Resonance technology platform, or T2MR®, for Bayer’s research and development efforts in blood coagulation disorders. This collaboration will develop tools and evaluate assays to help drive drug discovery and biomarker research for select Bayer hemostasis-rela... |